Aidence vs PathAI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Aidence employs 1-50 people, while PathAI has 300 employees.

PathAI has raised more in total funding at $255M, compared to Aidence's $20M — a gap of $235M. Combined, the two companies have completed 3 known funding rounds.

PathAI holds the higher Awaira Score at 62/100, compared to Aidence's 45/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 17-point gap that reflects meaningful differences in scale or traction.

Aidence was founded by Jeroen Vendrig in 2016. PathAI was founded by Andy Beck in 2016. Visit each company's profile on Awaira for a full founder biography.

Aidence: Aidence develops AI radiology software for lung cancer detection, building CE-marked and FDA-cleared deep learning algorithms that analyse CT scan images to identify and characterise pulmonary nodules requiring clinical follow-up. The Amsterdam company tools assist radiologists in national lung cancer screening programmes and in routine clinical CT reading, providing AI-generated nodule measurements, growth tracking, and malignancy risk scores that reduce reader variability and improve early detection rates.\n\nThe company raised approximately $20 million in venture funding and has deployed its Veye Chest algorithm across multiple European radiology networks and hospital systems participating in national lung cancer screening initiatives. Aidence received CE marking for its software as a medical device and has published clinical validation studies demonstrating performance that is non-inferior to specialist radiologist reads on lung nodule detection tasks.\n\nAidence competes in the AI radiology market alongside Annalise AI, Enlitic, Behold.ai, and Lunit, all of which target chest X-ray and CT reading assistance. The lung cancer screening market has expanded significantly as multiple European countries and the United States have implemented or planned national screening programmes for high-risk smokers, creating a growing workflow automation opportunity for AI lung nodule detection tools. The company was acquired by Coreline Soft, a South Korean medical AI company, as part of a broader consolidation in the AI radiology market. PathAI: PathAI is an AI healthcare company founded in 2016 that develops digital pathology solutions and AI-powered diagnostic tools for pathology labs and healthcare institutions. The company specializes in machine learning algorithms designed to assist pathologists in analyzing tissue samples and identifying diseases, particularly cancer. PathAI's core technology platform leverages deep learning and computer vision to process histopathology images, enhancing diagnostic accuracy and workflow efficiency. The company's primary offering includes software that integrates with existing laboratory information systems, enabling pathologists to use AI-assisted analysis for specimen evaluation. PathAI has developed partnerships with major healthcare systems and diagnostic laboratories, demonstrating clinical utility in oncology and other pathology specialties. The platform addresses critical challenges in pathology including diagnostic consistency, workload management, and access to specialized expertise in underserved regions. PathAI has raised $255 million in total funding as of its Series C stage, with valuation not disclosed. The company operates in the competitive digital pathology and AI diagnostics space, alongside competitors offering similar computational pathology solutions. The digital pathology market is experiencing significant growth driven by increasing diagnostic demands, laboratory automation trends, and regulatory acceptance of AI-assisted tools. PathAI's trajectory reflects broader momentum in AI-enabled healthcare diagnostics and precision medicine applications. PathAI combines deep learning with pathology workflows to create clinically integrated AI tools that assist rather than replace human pathologists.

Both Aidence and PathAI were founded in the same year — 2016. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

Aidence has approximately 1-50 employees, while PathAI has approximately 300. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Aidence and PathAI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.